bluebird bio (BLUE) Late-Breaker ASH Abstract Provides Proof-Of-Concept - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Wedbush Affirms bluebird bio (BLUE) at 'Outperform'; Late-Breaking ASH Data Bodes Will for bb2121
November 16, 2015 12:40 PM ESTWedbush affirms bluebird bio (Nasdaq: BLUE) with an Pit[erfpr, ratomg amd $165 price target after the company reported Phase 1 results in a late-breaking abstract from a NCI-sponsored study of anti-BCMA CAR-T cells dosed in multiple myeloma patients.
Analyst David M. Nierengarten noted, At lower doses (0.3-1 x 106 cells), 1 patient demonstrated a partial response (PR)... More
